Phoenix is no Kendall Square. Its biotech companies, ventures like OncoMyx Therapeutics and VisionGate, haven’t generated one-tenth the buzz of companies like Moderna or CRISPR Therapeutics.
But if congressional Democrats’ drug pricing reforms fail, the tiny biotechs that pepper the Grand Canyon State deserve an outsized bit of the credit.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
